ASBrS Recommends Cryoablation for Low-Risk Breast Cancer, Boosting ProSense® Adoption

summarizeSummary

IceCure Medical announced that the American Society of Breast Surgeons (ASBrS) updated its resource guide to recommend cryoablation for low-risk breast cancer, a move expected to accelerate commercial adoption of its ProSense® system.

check_boxKey Events

• ASBrS Recommends Cryoablation

  The American Society of Breast Surgeons (ASBrS) updated its 2026 Resource Guide, recommending cryoablation as an option for selected patients with biologically low-risk early-stage breast cancer.

• Validation for ProSense® System

  IceCure's ICE3 study and the FDA Advisory Panel's favorable vote on ProSense® cryoablation's benefit-risk profile were key factors in the ASBrS guidance update. ProSense® is the first and only FDA-cleared medical device for breast cancer treatment.

• Expected Commercial Acceleration

  The new medical society guidance is anticipated to further accelerate commercial adoption of ProSense® following its FDA clearance in October 2025, driving system placements and procedure volumes.

• Addresses Significant Patient Population

  ProSense® addresses a U.S. breast cryoablation patient population of approximately 200,000 women annually, including early-stage, low-risk breast cancer patients aged 70 and over, and those not suitable for surgery.

auto_awesomeAnalysis

The American Society of Breast Surgeons (ASBrS) updated its 2026 Resource Guide to recommend cryoablation as an option for selected patients with low-risk early-stage breast cancer. This is a significant validation for IceCure Medical's ProSense® system, which received FDA marketing clearance in October 2025 for this indication. The ASBrS recommendation, influenced by IceCure's ICE3 study, is expected to accelerate commercial adoption, increase system placements, and drive procedure volumes, providing a substantial positive catalyst for the company's growth and market penetration.